04:05:18 EST Wed 01 Dec 2021
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Aurora Cannabis Inc (2)
Symbol ACB
Shares Issued 197,360,688
Close 2021-01-27 C$ 14.32
Recent Sedar Documents

Aurora Cannabis, MedReleaf Australia enter supply deal

2021-01-27 17:11 ET - News Release

Mr. Miguel Martin reports

AURORA CANNABIS AND MEDRELEAF AUSTRALIA ANNOUNCE STRATEGIC AGREEMENT

Aurora Cannabis Inc. has entered into a strategic agreement with MedReleaf Australia. The companies have signed a five-year supply agreement, which provides for MedReleaf to act as the exclusive supplier in Australia of Aurora's MedReleaf, CanniMed and Aurora brands. Products covered by the agreement will be European Union good manufacturing practice certified and include dried flower, oils and soft gels, as well as future products employing new delivery mechanisms. The agreement does not require or include any capital investment by Aurora.

MedReleaf Australia, in which Aurora holds a 10-per-cent ownership stake, is a fully licensed, private company, operating in the Australian medical cannabis sector since 2016. MedReleaf and Aurora currently supply products to the Australian medical cannabis system. This agreement will advance that offering and extend availability of high-quality, medical cannabis to patients. MedReleaf is one of the six founding members of the trade association Medicinal Cannabis Industry Australia (MCIA).

"We are pleased to have established a long-term strategic relationship with MedReleaf to exclusively distribute the Aurora, CanniMed and MedReleaf brands in Australia," said Miguel Martin, chief executive officer of Aurora. "The team at MedReleaf have created an asset-light, sustainable growth platform in Australia to assist physicians, pharmacists and patients across the country in accessing the high-quality range of Aurora cannabis medicines."

Russell Harding, chief executive officer of MedReleaf, added: "Australia's medical cannabis system is well designed, well regulated and among the fastest growing in the world. Our strategic supply agreement with Aurora ensures that our patients will have reliable access to cannabis medicines with a worldwide reputation for quality and in accordance with the stringent requirements of Australia's Therapeutic Goods Administration. To support our companies' shared objectives in the Australian market, we will focus with diligence and discipline on continuing to expand our patient and prescriber base."

About Aurora Cannabis Inc.

Aurora is a global leader in the cannabis industry, serving both the medical and consumer markets. Headquartered in Edmonton, Alta., Aurora is a pioneer in global cannabis dedicated to helping people improve their lives. The company's brand portfolio includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler and Reliva CBD. Providing customers with innovative, high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, performance, wellness and recreational markets wherever they are launched.

Aurora's common shares trade on the Toronto Stock Exchange and the New York Stock Exchange under the symbol ACB, and the company is a constituent of the S&P/TSX Composite Index.

We seek Safe Harbor.

© 2021 Canjex Publishing Ltd. All rights reserved.